Xenon Pharmaceuticals (XENE) stock plummeted 6.53% in pre-market trading on Tuesday following the release of its first-quarter 2025 financial results. The clinical-stage biopharmaceutical company reported a wider net loss compared to the same period last year, despite beating analyst expectations.

According to the earnings report, Xenon posted a Q1 net loss of $0.83 per diluted share, compared to a loss of $0.62 in the year-ago quarter. While this loss was less than the $0.91 per share loss analysts had predicted, it still represents a significant widening of the company's deficit. Revenue for the quarter came in at $7.5 million, surpassing analyst expectations of $2.2 million, but investors seemed to focus more on the expanding losses.

Despite the negative market reaction, Xenon Pharmaceuticals maintains a positive outlook on its cash position. The company stated that based on current operating plans, it anticipates having sufficient cash to fund operations into 2027. However, this long-term view has not been enough to offset immediate concerns about the widening losses, leading to the sharp pre-market decline. As the market digests this financial information, investors will be closely watching how Xenon's clinical pipeline progresses and whether the company can narrow its losses in future quarters.